Dr. Richard Allan Flaiz, MD FACS Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 600 Nw 11th St, Suite E 21, Hermiston, OR 97838 Phone: 541-567-2270 Fax: 541-567-4153 |
News Archive
Standard chemotherapy is a blunt force instrument against cancer - and it's a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, throughout the body.
Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.
Two papers setting out recommendations for the reporting of epidemiological research are published in this week's PLoS Medicine, along with several other journals.
SeptRx, an emerging medical device company that has developed the SeptRx Intrapocket PFO Occluder (IPO), reported today that it has completed enrollment for its "InterSEPT" (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with CoRRect Medical GmbH for commercial distribution in Germany and Switzerland of the SeptRx IPO.
› Verified 7 days ago